Efficacy of Personalized Cancer Vaccine Confirmed by Phase 3 Success

Merck & Co. (MRK) and Moderna (MRNA)'s personalized neoantigen therapy, intismeran autogene (mRNA-4157/V940), has demonstrated both primary and secondary endpoints of recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in the phase 3 clinical trial (INTerpath-001) for high-risk resected melanoma. This is the first successful Phase 3 clinical trial of an mRNA cancer vaccine that significantly reduces the risk of recurrence and metastasis compared to monotherapy with Keytruda (pembrolizumab), a standard-of-care (SoC) immune checkpoint inhibitor. It is a remarkable achievement that has proven the efficacy of targeting 34 patient-specific neoantigens in the post-surgical adjuvant setting within clinical practice.

Bottlenecks and Scalability Limits Caused by Patient-Specific Production

Despite clinical success, the greatest barrier to commercialization is building a horizontal parallel expansion (scale-out) manufacturing process rather than relying on traditional scale-up methods. Intismeran is produced via an n-of-1 customized process that synthesizes individual mRNA following patient tumor biopsy and sequencing. To supply tens of thousands of patients simultaneously, advanced computational design, automated separation and purification, and a Chain of Identity (COI) system for patient-specific tracking must be in place. Reducing the turnaround time (TAT) from biopsy to medication administration to within 6–8 weeks is the key challenge determining treatment outcomes for patients with rapidly progressing severe diseases.

Lessons from Dendreon's Commercial Failure and Moderna's Dedicated Facility Strategy

Dendreon's prostate cancer cell therapy, Provenge (sipuleucel-T), which received FDA approval in 2010, serves as a painful precedent because the company went bankrupt within five years due to its cost of goods sold (COGS) accounting for approximately 77% of the selling price. To overcome this, Moderna has completed a dedicated automated facility in Marlborough, Massachusetts, and has begun operating parallel production lines with lead times measured in weeks. However, if global Contract Development and Manufacturing Organization (CDMO) partners and the entire raw material supply chain do not transition to a customized system, maintaining margins may be difficult due to high cost burdens. Ultimately, reducing costs through automation and standardized quality control will be the decisive keys to commercialization to protect pricing power and patient access.

The Wall of Cold Tumors and the Roadmap to Off-the-Shelf Therapies

Following Merck and Moderna's successes, BioNTech (BNTX) and Genentech (ROG) prematurely halted the phase 2 clinical trial of autogene cevumeran (BNT122), a personalized vaccine for colorectal cancer, due to an imbalance in overall survival (OS). Unlike melanoma, an immunologically "hot tumor" with a high tumor mutational burden (TMB), colorectal cancer, a "cold tumor," has very low neoantigen expression, making it extremely difficult to achieve efficacy with monotherapy. Therefore, the industry is striving to overcome manufacturing challenges by refining chemical-immune combination therapies and evolving its platform into off-the-shelf mRNA vaccines that target common mutations using accumulated biopsy big data.